Trial Profile
A Phase I Dose Escalation and Central Nervous System (CNS) Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients With Recurrent or Progressive Brain Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Brain cancer
- Focus Adverse reactions
- 08 Mar 2022 Status changed from active, no longer recruiting to completed.
- 11 Feb 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 11 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.